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Background: Minimization of blood loss during pancreatoduodenectomy requires careful surgical tech-
nique and specific preventative measures. Therefore, red blood cell (RBC) transfusions and operative time
are potential surgical quality indicators. The aim of the present study was to compare peri-operative RBC
transfusion and operative time with 30-day morbidity/mortality after pancreatoduodenectomy.
Methods: All pancreatoduodenectomies (2005 to 2008) were identified using the American College of
Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP). RBC transfusions and operative
time were correlated with 30-day morbidity/mortality.
Results: Pancreatoduodenectomy was completed in 4817 patients. RBC transfusions were given to
1559 (32%) patients (1–35 units). Overall morbidity and mortality rates were 37% and 3.0%, respectively.
Overall 30-day morbidity increased in a stepwise manner with the number of RBC transfusions (R = 0.69,
P < 0.01). Although RBC transfusions and operative times were not statistically linked (P = 0.87), longer
operative times were linearly associated with increased 30-day morbidity (R = 0.79, P < 0.001) and
mortality (R = 0.65, P < 0.01). Patients who were not transfused also displayed less morbidity (33%) and
mortality (1.9%) (P < 0.05).
Discussion: Peri-operative RBC transfusion after pancreatoduodenectomy is linearly associated
with 30-day morbidity. Longer operative time also correlates with increased morbidity and mortality.
Therefore, blood transfusions and prolonged operative time should be considered quality indicators
for pancreatoduodenectomy.
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Introduction
Despite a history now approaching 100 years,1,2 pancre-
atoduodenectomy remains a formidable and lengthy procedure
with substantial risks. While the mortality rate associated with this
operation has been dramatically reduced from more than 20% in
the 1970s to less than 3% in modern reports,3–5 peri-operative
morbidity has remained relatively consistent at approximately
40%.6,7 A clear improvement in outcomes is also observed when
pancreatoduodenectomies are performed in high volume centers
by experienced pancreatic surgeons.8,9
Allogenic blood transfusions increase the risk of infection,
acute lung injury and potentially cancer recurrence.10–15 While the
precise mechanism of transfusion-induced immunosuppression
is debated,16,17 significant operative blood loss that leads to a sub-
sequent need for blood transfusion has both short- and long-term
negative consequences. Because surgical blood loss is often con-
sidered a modifiable factor that may reflect surgical technique,
rates of peri-operative blood transfusion have been advocated as
robust quality indicators.17
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Extended operative duration has also been identified to nega-
tively impact outcomes after general surgical procedures.18–20 Both
an increased rate of infectious complications (surgical site infec-
tions, sepsis, septic shock, pneumonia and urinary tract infec-
tions), as well as a longer duration of hospital stay correlate with
operative time in patients undergoing both pancreatectomies and
biliary procedures.21 Moreover, these risks appear to increase in a
linear manner with lengthening operative times at 90-min inter-
vals.21 Therefore, the aim of this analysis was to identify the
associations between both peri-operative red blood cell (RBC)
transfusion and operative time, with 30-day morbidity/mortality
after pancreatoduodenectomy using the American College
of Surgeons-National Surgical Quality Improvement Program
(ACS-NSQIP).22
Methods
ACS-NSQIP
The ACS-NSQIP is a nationally validated, outcomes-based, risk-
adjusted, peer-controlled programme for the measurement and
enhancement of the quality of surgical care.23–26 One hundred and
thirty-six pre-operative (patient characteristics), intra-operative
(processes of care) and post-operative (adverse outcomes) vari-
ables were prospectively collected by trained, certified nurse
reviewers in the ACS-NSQIP. Patients younger than 16 years of age
were excluded. Quality is ensured by inter-rater reliability audits,
as well as online decision support so that the level of disagreement
is currently only 1.53% for all variables. Surgical clinical nurse
reviewers also ensured the validity of their data by assessing
physician documentation, and/or contacting patients directly.
Outcomes are assessed at 30 days after the index operation (e.g.
pancreatoduodenectomy), and highly standardized and validated
definitions were employed. Because all ACS-NSQIP data under-
goes a logistic regression analysis, observed-to-expected (O/E)
ratios can be calculated for morbidity and mortality. While
low ratios indicate superior quality of care, high ratios confirm
inferior care. ACS-NSQIP uses a systematic random sampling
process that employs an 8-day cycle, whereby the first 40 cases are
used to fulfil the inclusion and exclusion criteria at each partici-
pating centre. This process therefore excludes an over-sampling
of minor cases (i.e. cholecystectomy, inguinal hernia and breast
procedures).
Participant use file
The ACS-NSQIP Participant Use File (PUF) was queried to find
all patients who had undergone a pancreatoduodenectomy from 1
January 2005 to 31 December 2008. The pancreatoduodenectomy
procedure codes (48150, 48152, 48153, 48154) were used to iden-
tify all patients for analysis. Patient demographics and comorbidi-
ties were summarized. Operative procedure duration was queried
in 60-min intervals. Blood transfusions were quantified by the
specific number of transfused RBC units within 72 h of the opera-
tive procedure. Morbidity and mortality observed within 30 days
of a pancreatoduodenectomy were analysed. Morbidity included
organ space infections, wound disruption, cerebrovascular acci-
dent or stroke, myocardial infarction, cardiac arrest, pulmonary
embolism, ventilator dependence longer than 48 h, acute renal
failure, bleeding complications, sepsis, septic shock, superficial
surgical site infections, pneumonia, unplanned intubation, pro-
gressive renal insufficiency, urinary tract infection and deep
vein thrombosis. The overall complication pool is composed of
approximately two-thirds serious morbidity and one-third minor
complications. Expected morbidity and mortality are available in
the PUF based on logistic regressions of all procedures in the
database. Observed/expected (O/E) ratios for morbidity and mor-
tality were calculated for comparisons with regards to both RBC
transfusion and operative duration.
Statistical analysis
Analysis was performed using Stata version 8.0 (Stata Corp,
College Station, TX, USA). Normally or near-normally distributed
variables were reported as means and non-normally distributed
variables as medians. Means were compared using the Student’s
t-test and medians using the Mann-WhitneyU-test. Differences in
proportions among categorical data were assessed using Fischer’s
exact test. Correlations were determined with Pierson’s coeffi-
cients. A P-value less than 0.05 was considered to represent statis-
tical significance for all comparisons.
Results
Patient demographics and comorbidities
Over the 4-year study interval, 4817 patients who underwent a
pancreatoduodenectomy were tracked using the ACS-NSQIP reg-
istry. Three additional patients were excluded from the analysis as
a result of missing patient data. As seen in Table 1, the majority of
patients were functionally independent prior to their procedure.
Most patients also had 1 (29.2%), 2 (23.6%), 3 (14.3%), 4 (7.0%)
or more (5.5%) comorbidities. Specific definitions for these
comorbidities may be found at http://www.acsnsqip.org. A minor-
ity of patients received neoadjuvant chemoradiotherapy (3.6%) or
used chronic steroids (2.0%). Moreover, 20% of patients had lost
at least 10% of their pre-illness body weight prior to their pancre-
atoduodenectomy.
Blood transfusions
Thirty-two per cent (1559/4817) of patients received a RBC
transfusion within 72 h of their pancreatoduodenectomy. A
median of three units was utilized (range: 1–35) amongst patients
who actually received a blood transfusion (Fig. 1). The most
frequent number of units transfused was two followed by one.
Operative duration
Figure 2 displays the distribution of operative time. The mean
operative duration for a pancreatoduodenectomy was between
5 and 6 h. Fifty-nine per cent of the operations took between
4 and 7 h to perform.
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Outcomes – transfusion
Of the 4817 patients undergoing a pancreatoduodenec-
tomy, overall morbidity was 37% (1775/4817). Overall mortality
within 30 days was 3.0% (145/4817). The expected 30-day mor-
bidity was 42% and the expected mortality was 3.3%. Thus, the
morbidity O/E ratio was 0.89, and the mortality O/E ratio was
0.91. Overall 30-day morbidity increased in a stepwise manner
with the number of RBC transfusions (R = 0.69, P < 0.01), as
seen in Fig. 3a. Overall mortality was not statistically associated
Table 1 Patient demographics and comorbidities
Demographic
N 4782
Age, mean, y 64.3  4.3
BMI, kg/m2 26.6  5.8
General (%)
Diabetes 22.7
Smoking 21.9
Functionally independent (%)
Pre-illness 98.3
Pre-surgery 96.5
Cardiac (%)
HTN 52.1
CHF 0.3
MI 0.4
Respiratory (%)
Vent dependent 0.2
Dyspnea 9.0
Pneumonia 0.3
COPD 4.5
Renal (%)
Dialysis 0.3
Renal insufficiency 0.3
Ascites (%) 0.9
Bleeding disorder (%) 2.5
CHF, congestive heart failure; COPD, chronic obstructive pulmonary
disease; HTN, hypertension; MI, myocardial infarction; Vent dependent,
pre-operative ventilator dependent.
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Figure 1 Number of red blood cell units for patients who received a
transfusion
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Figure 2 Distribution of operative duration
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Figure 3 (a) Morbidity associated with blood transfusions (R = 0.69,
P < 0.01). (b Morbidity and mortality without and with blood trans-
fusions. *P < 0.00001 (no transfusion vs. transfusion)
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with transfusion of blood (R = 0.07, P = 0.44). These relation-
ships remained consistent in comparisons for observed/expected
morbidity (R = 0.82, P < 0.001) and mortality (R = 0.03,
P = 0.59) ratios, respectively. Patients who were not transfused
also displayed a lower morbidity (33%) and mortality (1.9%)
than patients receiving RBC transfusions (morbidity = 46%;
mortality = 5.3%) (P < 0.00001 for both comparisons), as seen
in Fig. 3b.
Outcomes – duration
Longer operative duration was linearly associated with both
increased 30-day morbidity (R = 0.79, P < 0.001) and mortality
(R = 0.65, P < 0.01) (Fig. 4a,b). Similar results were noted
in comparisons for observed/expected morbidity (R = 0.84,
P < 0.0001) and mortality (R = 0.74, P < 0.001). Although no
statistically significant association was observed between RBC
transfusion and operative duration (R = 0.001,P = 0.87), there was
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Figure 4 (a) Morbidity associated with operative duration (R = 0.79, P < 0.001). (b Mortality associated with operative duration (R = 0.65,
P < 0.01)
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a significant increase in the data variation at the extremes of
operative times (i.e. very brief, as well as extended duration cases).
Discussion
Analysis of the ACS-NSQIP for 4817 patients who underwent a
pancreatoduodenectomy from 2005 to 2008 demonstrated that
peri-operative RBC transfusion was associated with 30-day mor-
bidity in a stepwise manner. Moreover, longer operative times also
linearly correlated with increases in both 30-day morbidity and
mortality. This analysis suggests that peri-operative blood trans-
fusions and prolonged operative time should be considered
quality indicators for performance of pancreatoduodenectomy.
Throughout the nearly 100-year history of the pancre-
atoduodenectomy procedure,1,2 numerous modifications have
been reported. The goal of each update has been to decrease the
morbidity and mortality rates that often accompany this complex
procedure. Potential complications include, but are not limited to,
post-operative sepsis, haemorrhage, delayed gastric emptying, as
well as leakage from the pancreatico-enteric anastamosis. With
modern improvements in critical care, nutritional support and
percutaneous drainage techniques, peri-operative mortality has
been dramatically reduced from 20% to less than 3%.3–5 Unfortu-
nately, despite both technical and medical advancements, peri-
operative morbidity rates have remained relatively consistent at
approximately 40%.5–7
The NSQIP concept of prospectively collecting data on major
operations and then providing risk adjusted 30-day morbidity and
mortality outcomes for quality of care feedback originated in the
Department of Veterans Affairs (National Veterans Affairs Surgical
Risk Study).27–29 Subsequently, private sector health systems
adopted NSQIP in an attempt to reduce morbidity, mortality and
costs for participating hospitals.30 In 2004, the American College
of Surgeons initiated a modified version of NSQIP which cur-
rently includes data from approximately 250 hospitals, and is
being utilized for both quality of care assessment, as well as for
surgical research.31,22 Approximately 60% of these hospitals are
large academic medical centres. As a result, more than half of
the pancreatoduodenectomies being performed annually in the
United States are captured in this database.
Despite advances in surgical technique and peri-operative
care, a blood transfusion is still required in a significant number
of patients who undergo pancreatoduodenectomy. In this
ACS-NSQIP analysis, 32% of patients received a RBC transfusion
within 72 h of their operative procedure (median = 3 units).
The risks of allogenic blood transfusions are well documented
and include an increased incidence of post-operative infection,
acute lung injury and cancer recurrence.10–15 Unlike the poten-
tial transmission of infectious agents,32 these post-operative
effects appear to be the direct result of transfusion-related
immunosuppression.14–17 As a consequence of these data, as well as
results from a multicentre randomized trial indicating that a
transfusion trigger haemoglobin level of 7.0 g/dL is as safe as more
liberal thresholds in nearly all patients,33 ‘bloodless’ surgery is
being encouraged more frequently.17
In the context of hepato-pancreato-biliary (HPB) surgery,
a near paucity of literature explores the relationship between
RBC transfusion and outcomes. On univariate analysis, the Johns
Hopkins group identified blood loss as a predictor of subsequent
pancreatic fistula after pancreatoduodenectomy.34 Unfortunately,
this relationship was not maintained in a multivariate analysis. In
elective hepatic surgery, 10% to 33% of patients typically receive a
blood transfusion.35–39 On retrospective review, these transfusions
were shown to be associated with both an increase in peri-
operative morbidity and mortality, as well as in the length of
hospital stay.40 In a study attempting to predict the need for trans-
fusion in elective liver resections, a median of two units were
transfused when needed.41 Given the strong negative associations
between RBC transfusion and outcomes in non-pancreatic
surgery, it is not surprising that the ACS-NSQIP population dis-
played a stepwise increase in 30-day morbidity with increasing
RBC transfusions after pancreatoduodenectomy. Although a sta-
tistical increase in 30-day mortality was not observed, we believe
this observation is most likely the result of small sample sizes in
patient subgroups who died after receiving varying numbers of
RBC unit transfusions. This concept is strengthened by the obser-
vation that patients who received absolutely no blood had a sig-
nificantly lower 30-day morbidity and mortality rate than those
who were transfused with any volume of RBCs.
Clearly, pancreatoduodenectomies are technically challenging
procedures. As a result, intra-operative blood loss and, therefore,
subsequent RBC transfusions, are robust quality indicators
because they are ‘specific and measurable elements of practice that
can be used to assess quality of care’. 17,42 Moreover, this element of
care is also modifiable because it is often surgeon or anaesthesi-
ologist determined. As a result, it is one of the few modifiable
factors that we have available for both short- and long-term out-
comes.17 The need for a transfusion can also be altered by techni-
cal modifications such as minimizing blunt dissection, ensuring
intra-operative haemostasis and maintaining normothermia.
Non-technical approaches to reduce blood loss are also helpful
and include pre-operative improvement of haemoglobin levels
(iron and erythropoietin), minimizing redundant blood tests
(pre- and post-operative), reducing central venous pressures for
hepatic surgery, employing blood cell salvage devices and follow-
ing evidence-based guidelines for lower transfusion triggers.17
After general surgical procedures, increased operative duration
has been shown to predict infectious complications (surgical
site infections, sepsis, septic shock, pneumonia and urinary tract
infections).18–20 This association, as well as a longer duration of
hospital stay, has also been reported in patients undergoing both
pancreatectomies and biliary procedures.21 The specific operative
time needed to produce an increase in subsequent morbidity is
debated.18,20,21 Although no previous studies related to pancreatic
resection were available for comparison, the ACS-NSQIP study
cohort showed a strong linear correlation between operative
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duration and increased 30-day morbidity and mortality. While it
could be argued that operative time is most commonly a direct
result of patient anatomy and local disease progression, rather
than surgical technique, it is interesting to note that there was
no statistical association between operative duration and RBC
transfusion. If patient variables were the primary determinant of
operative time, one might also expect to see an increase in the
rate of blood transfusion with lengthened operative duration.
This study has several limitations. First, it is retrospective and
registry based; therefore the possibility of bias cannot be elimi-
nated. Second, the ACS-NSQIP is not designed to track and
evaluate pancreatoduodenectomy specific outcomes. As a result,
relevant complications such as pancreatic fistula and exocrine or
endocrine pancreatic dysfunction are not available for analysis. An
HPB-specific NSQIP option is currently under development.43
Third, the small number of patients who actually died within 30
days of their pancreatoduodenectomy under-powered our statis-
tical evaluation of the potential relationship between RBC
transfusion and mortality. Fourth, we were unable to analyse the
precise impact of additional operative components (i.e. diagnostic
laparoscopy and/or concurrent vein resection) because of a lack of
detail within the ACS-NSQIP registry. Fifth, although morbidity
and mortality are powerful indicators of quality, additional
metrics that may also be helpful in assessing quality (i.e. hospital
and surgeon volume, cost and emergency status) are not yet avail-
able in ACS-NSQIP.44,45 Finally, although a RBC transfusion is
considered a reasonable surrogate for peri-operative blood loss,
it remains an indirect measure and may be potentially influenced
by individual surgeon, anaesthesiologist, intensivist and trainee
transfusion thresholds (i.e. defiance of current level-one data
regarding indicated transfusion triggers33). However, peri-
operative transfusion does reduce the known inaccuracies in
surgeon-determined estimations of blood loss.46
In conclusion, 30-day morbidity is associated with both RBC
transfusion and extended operative duration in patients under-
going a pancreatoduodenectomy. A similar stepwise relationship
is present for 30-day mortality and operative duration. As a result,
limiting blood loss and avoiding prolonged operative times
should be goals for the pancreatic surgeon. These variables are
robust quality indicators for pancreatoduodenectomy.
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